2018/11/29 – CRI Report

Research Report on China’s Electronic Cigarette Industry, 2018-2022

admin — Thu, 29 Nov 2018 06:58:22 +0000

Description
Statistics show that the number of smokers in China is about 300 million to 350 million, and is still growing. More than 700 million non-smokers are exposed to second-hand smoke, and more than 1 million people die of smoking-related diseases every year. In 2017, the sales revenue of China’s cigarette industry reached CNY 1,435 billion (USD 208 billion)
An electronic cigarette is an electronic device that simulates the work of traditional cigarettes. It simulates tobacco smoke to provide the feeling of smoking and satisfy the smoker’s craving for nicotine. Therefore, it can be used as a substitute for traditional cigarettes to some extent. Compared with traditional tobacco, electronic cigarettes are much less harmful to human health, and cost only 2/3 or less.
Since the cigarette industry can bring huge taxes to the Chinese government, the Chinese government holds different attitudes towards different types of electronic cigarettes. Overall, it does not regulate vapes. While it prohibits the import and sale of heat-not-burn electronic cigarettes that are more similar to traditional cigarettes in flavor in fear that heat-not-burn electronic cigarettes would seriously impact the sales of traditional cigarettes. Therefore, heat-not-burn electronic cigarettes can only be sold online.
According to CRI’s market research, China is the world’s biggest base of electronic cigarette production. Accounting for over 90% of the global electronic cigarette production, in 2017, China-made electronic cigarettes exceeded 1.6 billion units. Despite the huge production volume, over 90% of China-made cigarettes are exported. Only a small portion is sold domestically. In recent years, as Chinese smokers raise their health consciousness, China’s electronic cigarette market is growing rapidly. From 2013 to 2017, the market size of electronic cigarettes in China grew from less than CNY 1 billion to more than CNY 4 billion. Although there are some leading enterprises in China’s electronic cigarette industry, the overall market concentration ratio is low, and the growth potential is huge.
As Chinese smokers are more concerned about health, and electronic cigarettes contain much less harmful substances such as nicotine, electronic cigarettes will be welcomed by many smokers, especially young smokers who prefer diversified tastes and plentiful smoke. Moreover, the advancement in electronic cigarette technology can reduce production costs and enhance flavors, thereby cutting the migration costs for traditional smokers. It is expected that as the consciousness of smoking ban is strengthened, the Chinese government will loosen up on its electronic cigarette policies, which will promote the development of China’s electronic cigarette industry. It is expected that with the continuous strengthening of the smoking ban, the Chinese government’s policy on e-cigarettes will gradually become looser, which will help promote the development of China’s e-cigarette industry. If 10% or 30 million to 35 million of Chinese smokers turn to electronic cigarettes, the potential market size will be above USD 15 billion.

Topics Covered:
– Development environment of China’s electronic cigarette industry
– Supply of and demand for electronic cigarettes in China
– Export of electronic cigarettes in China
– Competition on China’s electronic cigarette market
– Major factors influencing the development of China’s electronic cigarette industry
– Prospect of China’s electronic cigarette market from 2018 to 2022

The post Research Report on China’s Electronic Cigarette Industry, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Rosuvastatin Market, 2018-2022

admin — Thu, 29 Nov 2018 06:58:13 +0000

Description
Rosuvastatin was first developed by Japanese company Shionogi & Co., Ltd. in the late 1980s. In Jun. 1998, Shionogi & Co., Ltd. transferred the right to develop, market and sell Rosuvastatin worldwide to AstraZeneca. The development code of Rosuvastatin by AstraZeneca is ZD-4522. Rosuvastatin was first approved in the Netherlands on Nov. 7, 2002, approved by the Health Council of Canada in Feb. 2003, and by the FDA on Aug. 12, 2003. The trade name of AstraZeneca’s branded Rosuvastatin is Crestor.
After Rosuvastatin was launched, its sales value grew sharply. Rosuvastatin has become a key product of statins. In 2012, Rosuvastatin became the number one lipid-lowering drug in the world with a sales value of USD 6.2 billion.
With the improvement of living standards and the change in diet, from 1978 to 2018, Chinese people’s blood lipid levels kept rising, and the incidence of dyslipidemia increased significantly. The overall incidence of dyslipidemia in Chinese adults is up to about 40%. As dyslipidemia is a major cause of the development of coronary heart disease, strokes and other atherosclerotic lesions, active treatment of hyperlipidemia can reduce the incidence of these diseases. In China, Rosuvastatin is used to treat primary hypercholesterolemia (Type IIa, including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (Type IIb) that cannot be properly controlled via diet control and non-drug treatments (e.g. sports therapy and weight loss). In the treatment of homozygous familial hypercholesterolemia, it complements the diet control and other lipid-lowering measures (such as LDL removal), or serves as an alternative when these measures do not work.
According to CRI, Rosuvastatin has been growing rapidly since it entered China, with its sales revenue increasing from less than CNY 2 million in 2007 to more than CNY 1.1 billion in 2017. At present, China’s Rosuvastatin market is dominated by IPR PHARMACEUTICALS INC. (ASTRAZENECA), Lunan Better Pharmaceutical Co., Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd., Zhejiang Jingxin Pharmaceutical Co., Ltd., etc. Pfizer has the largest market share by sales value which was about 67% in 2017.
It is expected that as more Chinese people suffer from hyperlipidemia, China’s Rosuvastatin market will continue to grow in the next few years.

Topics Covered:
– Situation of hyperlipidemia in China
– Market size of Rosuvastatin in China
– Competitive landscape of China’s Rosuvastatin market
– Prices of Rosuvastatin in China
– Prospect of China’s Rosuvastatin market from 2018 to 2022

The post Investigation Report on China’s Rosuvastatin Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Glimepiride Market, 2018-2022

admin — Thu, 29 Nov 2018 06:58:05 +0000

Description
Glimepiride is a third-generation sulfonylurea insulin secretagogue. Sanofi’s brand-name drug (trade name: Amaryl) have been marketed in many countries after it was approved by the FDA (U.S. Food and Drug Administration) on Nov. 30, 1995. Glimepiride is the sulfonylurea hypoglycemic agent that has best clinical effectiveness as well as the first sulfonylurea approved by the FDA to be used together with insulin. It does much better in sensitizing and simulating insulin than other sulfonylureas. For type 2 diabetic patients with insulin resistance (reduced glucose utilization in peripheral tissues), Glimepiride reduces blood glucose by sensitizing and simulating insulin. For type 2 diabetic patients with insulin secretion dysfunction, Glimepiride reduces blood glucose by stimulating insulin secretion.
According to CRI, with the development of China’s economy, the rise of urbanization level, and the aging of population, the life style of Chinese people is changing, which increases the obese population and the incidence of diabetes in China. It is estimated that the number of type 2 diabetic patients in China had surpassed 1 million by the end of 2017, and is growing by 1.5 million to 2 million every year. The growing number of diabetics in China promotes the growth of the antidiabetic drug market.
According to CRI, generic products have sprung up one after another since 2004 when Sanofi (Beijing) Pharmaceutical Co., Ltd. launched Amaryl in China. In 2017, the market size of Glimepiride in China was about CNY 302 million. There are over 10 Glimepiride manufacturers in China. The major market players include Sanofi (Beijing) Pharmaceutical Co., Ltd., Jiangsu Wanbang Biopharmaceuticals Co., Ltd., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., and Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. By sales value, in 2017, Sanofi (Beijing) Pharmaceutical Co., Ltd.’s Amaryl captured more than 80% share of China’s Glimepiride market.
It is expected that as the number of diabetics continues to grow, China’s Glimepiride market will have huge growth potential in the next few years.

Topics Covered:
– Situation of diabetes in China
– Sales of Glimepiride in China
– Competition on China’s Glimepiride market
– Prices of Glimepiride in China
– Forecasts on China’s Glimepiride market from 2018 to 2022

The post Investigation Report on China’s Glimepiride Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Montelukast Market, 2018-2022

admin — Thu, 29 Nov 2018 06:58:00 +0000

Description
More than 300 million people in the world are suffering from seasonal asthma of varying degrees. The number is higher in countries with severe environmental pollution and high tobacco consumption. Asthma and allergic rhinitis are common nowadays. Owing to heavy air pollution, the incidences of these diseases are increasing year by year.

Montelukast, developed by MSD, is widely used in the treatment of allergic rhinitis and asthma. As a selective leukotriene D4 receptor antagonist, it selectively binds to the leukotrienes in the airway, blocks the action of allergic mediators, reduces airway inflammation, and makes the airway unobstructed. In 1998, Montelukast sodium tablets (10 mg) and chewable tablets (5 mg) were approved by the FDA and first marketed in the U.S. in the trade name of “Singulair”. In 2000 and 2002, Montelukast chewable tablets (4 mg) and granules (4 mg) were approved for sale, mainly for the prevention and long-term treatment of asthma in adults and children aged above 2.

In 1999, MSD’s Montelukast chewable tablets (5mg) and tablets (10mg) were approved to enter China in the trade name of “Singulair”, followed by Montelukast chewable tablets (4mg) and granules (4mg). In 2006, the generic Montelukast tablets (10mg) and chewable tablets (5mg) by Sichuan Otsuka Pharmaceutical Co., Ltd. were approved to be sold in the trade name of “Bystine”. Many other companies in China have also filed applications for generic Montelukast.

According to CRI’s market research, from 2005 to 2010, the annual sales value of Montelukast in China grew at a CAGR of more than 40%. As competing products emerged, the growth rate slowed down from 2011 but stays above 10%. In 2017, the market size of Montelukast was about CNY 552 million. The market was dominated by MSD, Lunan Better Pharmaceutical Co., Ltd., and Sichuan Otsuka Pharmaceutical Co., Ltd. Declining in recent years, the market share by sales value of MSD was close to 73%.

According to statistics, there are more than 30 million asthma patients and 300 million to 400 million patients with allergic rhinitis in China. And the numbers will continue to rise with increasingly serious environmental pollution. In China, Montelukast is considered as one of the best anti-asthmatic drugs, which promises huge market potential.

Topics Covered:
– Situation of respiratory diseases in China
– Supply and sales of Montelukast in China
– Prices of Montelukast in China
– Competition on China’s Montelukast market
– Market share of Montelukast manufacturers in China
– Prospect of China’s Montelukast Market, 2018-2022

Global Digital Respiratory Devices Market: Focus on Sensors, Smart Inhalers and Nebulizers, Application, 9 Countries Data, and Competitive Landscape – Analysis and Forecast, 2021-2030

The post Investigation Report on China’s Montelukast Market, 2018-2022 first appeared on CRI Report.